drugset / Trial / NCT03392389
Safety, Reactogenicity, and Immunogenicity of mRNA-1653 in Healthy Adults
RandomizedSequentialDouble-blindPrevention
Summary
This clinical study will assess the safety, reactogenicity and immunogenicity of mRNA-1653, a combined human metapneumovirus and human parainfluenza virus type 3 vaccine in healthy adults.
Timeline
- Start
- 2017-12-04
- Primary completion
- 2019-07-29
- Completion
- 2019-07-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | mRNA-1653 | Vaccine | — | — |